The development of a major life science cluster at Canary Wharf continues to build momentum with a range of life sciences focused start-ups and scaleup businesses joining the growing community of technology businesses at its specialist co-working and office hub, Level39. Based in One Canada Square, Level39 is a flexible workspace and tech community. Launched by Canary Wharf Group ten years ago, it is now home to over 180 start-ups and scaleups innovating in FinTech, Cyber Security, CleanTech, Blockchain, Life Sciences and HealthTech. This evening Level39 will also be hosting the first Health & Life Sciences Meet-up in Canary Wharf, bringing together over 100 start-ups, scaleups and investors to discuss growth and investment into the sector.
Level39 is now fast becoming a go-to destination for life sciences-based companies, welcoming a raft of new members including TC BioPharm, the clinical stage biotechnology company; Neural Rays, the ethical AI company; and Sanius Health, a health tech company dedicated to improving rare diseases treatment.
The growing life sciences ecosystem at Level39 will soon also be accompanied by the occupiers within the new life sciences innovation centre at 20 Water Street, which is launching in June this year and will provide highly flexible and best in class laboratory space. This is further endorsement of Canary Wharf Group’s strategy, which, in joint venture with Kadans, is looking to establish a world leading health and life sciences cluster at Canary Wharf centred around their planned development of a new 823,000ft² commercial laboratory building at North Quay.
The new 23-storey building will be delivered in 2026 and will set a new benchmark in the development of life sciences laboratories and workspace. Importantly, it will be a laboratory building at its core, with designs allowing for lab space to be available on all floors.
The 3.3 hectare North Quay site is located on the doorstep of Canary Wharf’s new Elizabeth Line station, providing excellent connectivity to central London and Heathrow. Designed by Kohn Pedersen Fox Associates (KPF), the new building will be developed to the highest sustainability and technological standards. The project will leverage Kadans’ experience of curating multi-let lab projects with vibrant health and life science ecosystems housing SMEs and academics as well as global healthcare and pharmaceutical companies.
Richard Archer, Managing Director of Offices, Canary Wharf Group, said: “Our strategy is to make Canary Wharf one of Europe’s leading centres for life sciences, and establishing an ecosystem of inter-connected companies is a key element to achieving that goal. Having welcomed a raft of new members at Level39, we are building real momentum in growing this cluster whilst working seamlessly in tandem with the development of the new vertical life sciences campus at North Quay. We look to forward to hosting many of the new start-up and scaleup businesses occupying Level39 at our Health & Life Sciences meet up today.”